bioihbjkbjnl/mcl2 huggingface dataset:
The Effects of Exercise Timing and Intensity on Motor Learning in Healthy Adults.
Condition: Healthy
Study type: Interventional

Summary: 
      The purpose of this study is to compare of the effects of a single session of aerobic
      exercise with different intensity and timing on motor learning processes in healthy young
      adults.
    

Detailed description: 
      Long-term aerobic training are associated with improved motor learning. Recent studies have
      shown that even a single bout of moderate or high ıntensity aerobic exercise can lead to
      immediate improvements on motor learning. On the other hand, there is still insufficient
      knowledge about whether aerobic exercise should occur before or after motor practice and what
      the intensity of aerobic exercise should be. In this study, the ınvestigators examined the
      effects of a single bout of low and moderate intensity aerobic exercise applied before or
      after motor practice on golf putting task. Additionally, the ınvestıgators evaluated the
      effects of sleep quality on motor learning and the acute effects of the exercise on
      cognition. 75 young adults were divided into five groups: two groups that did low or moderate
      intensity aerobic exercise before motor practice (LOW-MP, MOD-MP), two groups that did
      aerobic exercise after motor practice (MP-LOW, MP-MOD), and non-exercise control group. The
      acquisition practice consisted of six blocks of ten golf puttings. The retention was also
      evaluated both 1 day and 7 days after the experimental day with one block each. The putting
      performance was measured with accuracy and consistency error scores were computed for each
      acquisition and retention block. The sleep quality of the night before and the experimental
      day were evaluated using the Richard Campbell Sleep Scale.
    

Intervention name(s): low ıntensity aerobic exercise; moderate ıntensity aerobic exercise
Intervention type(s): Behavioral; Behavioral
Intervention description(s): The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 57-63% maximum heart rate.; The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 64-76% maximum heart rate.
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: 75 young adults were divided into five groups: two groups that did low or moderate intensity aerobic exercise before motor practice (LOW-MP, MOD-MP), two groups that did aerobic exercise after motor practice (MP-LOW, MP-MOD), and non-exercise control group.
Masking: Single (Participant)
Primary purpose: Other
Keywords: exercise; motor skills; retention; Young Adult; Sleep Quality
Is Prolonged Period of Prone Position Effective and Safe in Mechanically Ventilated Patients With SARS-COV-2?
Condition: COVID-19 Acute Respiratory Distress Syndrome
MeSH terms: Respiratory Distress Syndrome; Respiratory Distress Syndrome, Newborn; Acute Lung Injury
Study type: Interventional

Summary: 
      the aim of the study is to assess safety and efficacy of prone position ventilation beyond
      the usual 16 hrs in patients with SARS-COV-2
    


Intervention name(s): prolonged prone position ventilation
Intervention type(s): Procedure
Intervention description(s): patients mechanically ventilated with SARS COV 2 will be subjected to a longer than usual period of prone position ventilation
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Effect of Local Application of Simvastatin Versus Bone Powder on Implant Bone Changes
Condition: Dental Caries Extending to Pulp; Dental Implant Failed
MeSH terms: Dental Caries
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      This study is conducted A- To investigate that PRF loaded with osteopromotive pharmacological
      drug can be a great aid in implant rehabilitation, and whether it could be a replacement for
      the other high price bone graft materials or not.

      This will be done through:

        1. Measuring bone changes around the implant by cone beam

        2. Measuring change in bone density around the implants

      B- Evaluate the effect of statins on osteoblasts activity and expression of various
      osteogenic products in vitro.
    

Detailed description: 
      Twenty four patients requiring rehabilitation by immediate implantation in an extraction
      socket were recruited for this study. The Patients were divided into three groups (n=8), For
      the first group; immediately after extraction, PRF alone was added into the extraction socket
      prior to implant insertion. For the second group, PRF + 1.2mg Statin powder are inserted into
      the extraction site before implant insertion. For the third Group; PRF + Bone powder are
      inserted into the extraction site before implant insertion. A conebeam CT was used to
      evaluate the effect on bone changes and bone density around implant sites, for every patient
      in all implant groups immediately after the surgery and at follow-up time. In vitro
      experiment: isolation of human Adipose mesenchymal stem cells (hAd-MSCs), characterization
      and osteogenic differentiation will be done. The cells were divided into two groups one
      control group and the other statin group. Osteogenic markers were measured in both groups and
      statistical analysis performed
    

Intervention name(s): Simvastatin
Intervention type(s): Drug
Intervention description(s): Comparing Simvastatin powder with PRF to Bone Powder with PRF on Peri-implant Bone
Intervention MeSH terms: Simvastatin
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary purpose: Treatment
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
Condition: Ischemic Stroke
MeSH terms: Stroke; Ischemic Stroke; Cerebral Infarction; Ischemia
Study type: Interventional
Phase: Phase 2

Summary: 
      Phase IIa clinical trial, pilot, single centre, prospective, randomized, double-blind,
      placebo-controlled, with sequential inclusion of patients
    

Detailed description: 
      20 Patients presenting with a moderate-severe acute ischemic stroke who will be randomized in
      a 1:1 proportion to intravenous treatment with allogeneic stem cells from adipose tissue or
      to placebo (vehicle).
    

Intervention name(s): Allogenic mesenchymal stem cells from adipose tissue; Placebo
Intervention type(s): Drug; Drug
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Cerebral infarction; Cellular therapy
Antidiabetic Potiential of Moringa and Dom Extract
Condition: Diabetes
Study type: Interventional
Phase: Early Phase 1

Summary: 
      The Antidiabetic potential of Hyphaene thebaica fruits and Moringa oleifera leaves will be
      investigated in diabetic patients (type 2). The patients will be maintained on tea of both
      drugs for 6 weeks. The fasting blood glucose levels of patients will be checked on a daily
      basis. Other blood biomarkers will be also reported such as insulin concentration, Lipid
      profile, liver enzymes, c-peptide and glycated hemoglobin
    


Intervention name(s): MorDom
Intervention type(s): Dietary Supplement
Intervention description(s): oral powder in tea bags contains 4gm twice daily (equal concentration of each drugs)
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Supportive Care
Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease
Condition: Graft vs Host Disease; Blood and Marrow Transplant (BMT)
MeSH terms: Graft vs Host Disease
Study type: Interventional
Phase: Phase 2

Summary: 
      Evaluate the clinical activity of sirolimus in combination with cyclosporine and
      corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
    

Detailed description: 
      An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD
      Following Allogeneic Bone Marrow Transplant
    

Intervention name(s): high dose chemotherapy and autologous hematopoietic cell transplant
Intervention type(s): Procedure
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Effects of Intraarticular Botulinum Toxin A in Ankle Osteoarthritis
Condition: Ankle Osteoarthritis
MeSH terms: Osteoarthritis
Study type: Interventional

Summary: 
      The purpose of this study is to compare the effects of intraarticular Botulinum Toxin A
      versus intraarticular hyaluronate plus rehabilitation exercise in patients with ankle
      osteoarthritis.
    

Detailed description: 
      Recent pilot studies report that intraarticular injection of Botulinum Toxin A into painful
      joints of patients with various types of arthritis leads to significant and durable
      improvement in pain and function and is safe to use. To date, there is no published
      literature that evaluate the effects of intraarticular Botulinum Toxin A in the treatment of
      ankle OA. Sun el al reported that 3 or 5 weekly injection of hyaluronate may improve pain and
      physical function in patients with ankle OA and the treatment effects may last for 6 months.
      The effect of one injection of hyaluronate plus exercise had never been studied. The purpose
      of this study is to compare the effects of intraarticular Botulinum Toxin A versus
      intraarticular hyaluronate plus rehabilitation exercise for patients with ankle OA.
    

Intervention name(s): Botulinum Toxin A (Allergan, Inc, Irvine CA); Hyalgan (Hyalgan, Fidia , Italy)
Intervention type(s): Drug; Drug
Intervention description(s): patients received intraarticular injections by the same experienced physician using aseptic procedures.; The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.
Other intervention name(s): 100 units of Botulinum Toxin A in 2 cc NS; 2 ml Hyalgan, molecular weight 500-730kDa, Fidia , Italy
Intervention MeSH terms: Botulinum Toxins; Botulinum Toxins, Type A; abobotulinumtoxinA; Hyaluronic Acid
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: osteoarthritis, botulinum toxin, hyaluronate
Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII
Condition: Hemophilia A
MeSH terms: Hemophilia A
Study type: Interventional
Phase: Phase 4

Summary: 
      Patients with severe hemophilia and inhibitors can be treated effectively by Activated
      Prothrombin Complex Concentrates (APCC, eg. FEIBA) or High dose recombinant factor VIIa
      (rFVIIa). Rarely, such patients develop refractoriness to these products for whom therapy
      with sequential FEIBA and rFVIIa has been recently suggested.

      The impetus for the present report was a hemophilia A patient with high titer inhibitor
      (1300BU) who had life threatening hematuria that was resistant to repeated doses of 400µg/kg
      rFVIIa up to a cumulative dose of 1200 µg/kg given over 6-9 hours.

      Thrombin generation (TG) tested in vitro was consistent with resistance to high
      concentrations of rFVIIa but yielded good response to combinations of low doses of
      rFVIIa+FEIBA. In a desperate attempt to control the bleeding, concomitant therapy of 25 U/kg
      FEIBA and 40µg/kg rFVIIa was infused and resulted in arrest of bleeding within minutes. Over
      a span of about one year the patient has been successfully treated by this combination for
      more than 200 bleeding episodes in muscles and joints.
    

Detailed description: 
      Inhibitor patients with HR inhibitors were eligible for study enrollment. After consent blood
      was drawn and ex- vivo spiked with rFVIIa/FEIBA and combinations, assayed by thrombin
      generation tests.

      The combination yielding sufficient hemostasis was depicted for patients' therapy of future
      bleeding episodes.

      Following actual therapy hemostasis and safety parameters were monitored.
    

Intervention name(s): rFVIIa-FEIBA therapy for hemophilia A inhibitors; FEIBA- Activated Prothrombin Complexes
Intervention type(s): Drug; Drug
Intervention description(s): DOses tailored per ex vivo spiking thrombin generation
Other intervention name(s): NOVOSEVEN; APCC
Intervention MeSH terms: Thrombin; Anti-inhibitor coagulant complex; Factor VIII
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial
Condition: Allergy to Cat Dander
Study type: Interventional
Phase: Phase 1

Summary: 
      This study is placebo controlled, double blind, randomised, two arm dose escalation of a new
      product for specific immunotherapy in cat allergic patients
    


Intervention name(s): IVN201; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Intralymphativ injection of the study drug
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months
Condition: Influenza
MeSH terms: Influenza, Human
Study type: Interventional
Phase: Phase 3

Summary: 
      A random, blind and positive control design was adopted.the investigators will assess the
      safety and immunogenicity of 2 doses of an quadrivalent influenza vaccine virus subunit in
      children aged 6 to 35 months.

      A total of 2,772 subjects in the 6-35 month age group were randomly divided into experimental
      vaccine 1, experimental vaccine 2 and control vaccine groups at a ratio of 1:1:1, and
      received the corresponding vaccine respectively. 2 doses in the whole course, 28 days apart.

      Safety observation: All subjects received 30 minutes of immediate response observation after
      each dose of vaccine and 0-7 days of systematic active safety observation; After 7 days of
      vaccination, the incidence of adverse events was observed by combining regular weekly
      follow-up with subject's voluntary report. Safety observation was conducted for 0-28/30 days
      after each dose of vaccine. Serious adverse events (SAE) were collected within 6 months after
      the first dose was administered.

      Immunogenicity observation: Blood samples were collected before the first dose and 28 days
      after the full dose for influenza virus HI antibody detection.

      Observation of immune persistence: Blood samples of 3 and 6 months after immunity were
      collected for influenza virus HI antibody detection.
    


Intervention name(s): Quadrivalent influenza virus subunit vaccine; Quadrivalent influenza virus subunit vaccine; Quadrivalent split influenza virus vaccine
Intervention type(s): Biological; Biological; Biological
Intervention description(s): This vaccine（0.5ml） is produced by Ab&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection; This vaccine（0.25ml） is produced by Ab&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection; This vaccine（0.25ml） is produced by HUALAN BIO。Subjects will receive two doses of quadrivalent split influenza virus vaccine administered 28 days apart by intramuscular injection
Intervention MeSH terms: Vaccines
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Prevention
The Effect of Reading Book on Preoperative Anxiety
Condition: Preoperative Anxiety
MeSH terms: Anxiety Disorders
Study type: Interventional

Summary: 
      Observe the effects of reading an informative story book on preoperative anxiety and maternal
      anxiety
    

Detailed description: 
      Observe the effects of reading an informative story book at preoperative period on
      preoperative anxiety by m-YPAS in the holding area and on maternal anxiety by STAI in the
      holding area.
    

Intervention name(s): Informative story book; Non Informative Story Book
Intervention type(s): Other; Other
Intervention description(s): Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.; Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
Other intervention name(s): Elif Ameliyat Oluyor; Çiftlik Öyküleri-Kamp
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Other
Virtual Reality and Fatigue Education
Condition: Fatigue; Anxiety
MeSH terms: Fatigue
Study type: Interventional

Summary: 
      It was planned to evaluate the effect of distraction intervention with virtual reality and
      fatigue education on the level of fatigue and anxiety in children with cancer.
    

Detailed description: 
      H1: The fatigue scores of the patients who received distraction intervention with virtual
      reality and were given fatigue training were lower than the group that was given only fatigue
      training.

      H2: The anxiety scores of the patients who received distraction intervention with virtual
      reality and were given fatigue training were lower than the group that was given only fatigue
      training.

      Data collection After the child and his family are informed about the study, their written
      informed consent will be obtained. All children included in the study on the day (day 0)
      prior to the start of chemotherapy treatment will be given training on fatigue. In order to
      determine how he felt and his level of fatigue on the day of the training, it was planned to
      apply the Child Anxiety Scale-State (CAS-D), Child Fatigue Scale-24 Hours and Visual Fatigue
      Scale at 16.00 (pretest).

      After randomization is achieved, a distraction intervention will be applied once a day for
      10-15 minutes with virtual glasses on the 1st, 2nd and 3rd days of the chemotherapy treatment
      of the children in the study group. This intervention is planned to take place between
      14.00-15.00 in the afternoon.
    

Intervention name(s): virtual reality and fatigue education; fatigue education
Intervention type(s): Device; Behavioral
Intervention description(s): virtual reality distraction for 3 days and fatigue education for children; fatigue education for children
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Investigator)
Primary purpose: Prevention
Keywords: virtual reality
Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure
Condition: Cardiac-induced Edema
MeSH terms: Heart Failure; Edema, Cardiac; Edema
Study type: Interventional
Phase: Phase 3

Summary: 
      A Multicenter, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy
      and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients with Heart
      Failure
    

Detailed description: 
      Interventional, phase III, 2-arm parallel group, placebo-controlled, multicenter, randomized
      1:1, double-blind study, comparing Tolvaptan and placebo in hospitalized HF patients with
      signs or symptoms of congestion at the time of randomization in spite of standard
      therapy.This study intends to demonstrate that a repeated 4-day treatment with Tolvaptan in
      addition to standard of care (SOC) is superior to SOC alone for the treatment of clinical
      relevant cardiac-induced volume retention parameters in patients hospitalized for worsening
      HF initially treated with conventional therapy including diuretics.
    

Intervention name(s): Tolvaptan; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Tolvaptan 15mg once daily; Placebo
Other intervention name(s): Samsca
Intervention MeSH terms: Tolvaptan
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
Condition: Hypertension, Pulmonary
MeSH terms: Pulmonary Arterial Hypertension; Hypertension, Pulmonary; Hypertension
Study type: Interventional
Phase: Phase 4

Summary: 
      The MOTION study was a prospective, Phase IV study for patients with Pulmonary Arterial
      Hypertension (PAH). The study was designed to further explore patient-reported outcomes in
      PAH subjects who were not on active treatment and living in the United States. In addition,
      the study explored the use of new telemetric technology (Accelerator band) to evaluate if
      this technology correlates with improvements in 6 Minute Walking Distance 6MWD in patients
      with PAH.
    


Intervention name(s): Riociguat (Adempas, BAY63-2521)
Intervention type(s): Drug
Intervention description(s): Participants received therapy with riociguat during a 10-week titration phase. The starting dose for riociguat for all patients was 0.5 milligram (mg) three times a day (TID). The dose of riociguat was increased every 2 weeks in 0.5 mg increments to 1.0, 1.5, 2.0, and 2.5 mg until patients reached their individual optimal dose based on their systolic blood pressure and well-being. After reaching their optimal dose, patients then entered a maintenance phase and remained on this dose for an additional 14 weeks. End of treatment was reached at Visit 10 after 24 weeks of treatment with riociguat.
Intervention MeSH terms: Riociguat
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Pulmonary Hypertension,Riociguat,Living with Pulmonary Hypertension Questionnaire